Prevnos
Jersey City
About Prevnos
Prevnos is a biotechnology company operating within the in vitro diagnostics sector. Prevnos engages within the cancer genetics and cytogenetics space, creating novel fluorescence in situ hybridization (FISH) assays for clinical and research use. As the inventors of the world's first Hybrid Fusion FISH™ tests for cancer genetics and diagnostics, Prevnos enables 90%+ efficiency in FISH testing while reducing the overall economic burden for such tests. Prevnos is also the inventor of the Retina Microscope™, the world's most economical and first fluorescence scope to use transparent OLED displays and foil-glass projection displays operating through a thin-client PC, conveniently and optimally suited for a FISH dark room. It is the first FISH scope in its class.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Funding stage: Seed
- Last round: Seed (Mar 2016)
- Website: prevnos.com
Industries & Categories
Biotechnology, Energy Efficiency, Genetics, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/prevnos-3038669 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.